The Pigmented Lesion Assay (PLA, sensitivity 91-95%, specificity 69-91%, negative predictive value 99%) is a commercially available, non-invasive gene expression test that helps dermatologists guide pigmented lesion management decisions and rule out melanoma. Earlier studies have demonstrated high clinical utility and no missed melanomas in a 3- 6-month follow-up period. We undertook the current investigations to provide 12-month follow-up data on PLA(-) tests, and to further confirm utility. A 12- month chart review follow-up of 734 pigmented lesions that had negative PLA results from 5 US dermatology centers was performed. Thirteen of these lesions (1.8%) were biopsied in the follow-up period and submitted for histopathologic review. None of the lesions biopsied had a histopathologic diagnosis of melanoma. The test’s utility was studied further in a registry (N=1575, 40 US dermatology offices, 62 participating providers), which demonstrated that 99.9% of PLA(-) lesions were clinically monitored, thereby avoiding a surgical procedure, and 96.5% of all PLA(+) lesions were appropriately biopsied, most commonly with a tangential shave. This long-term follow-up study confirms the PLA’s high negative predictive value and high utility in helping guide the management of pigmented lesions to avoid unnecessary surgical procedures.
|Original language||English (US)|
|Journal||Dermatology Online Journal|
|Publication status||Published - May 1 2019|
- Clinical utility
- Gene expression
- Rule-out test
ASJC Scopus subject areas